Xaviar M. Jones MD , Russell G. Rogers PhD , Kara Tsi BS , Thassio Mesquita PhD , Alberto Marchevsky MD , Alessandra Ciullo PhD , Salwa Soussi PhD , Nunzio Bottini MD, PhD , Francesco Boin MD , Ahmed G.E. Ibrahim PhD, MPH , Eduardo Marbán MD, PhD
{"title":"Macrophages Contribute to Cardiac Fibrosis and Diastolic Dysfunction in Systemic Sclerosis","authors":"Xaviar M. Jones MD , Russell G. Rogers PhD , Kara Tsi BS , Thassio Mesquita PhD , Alberto Marchevsky MD , Alessandra Ciullo PhD , Salwa Soussi PhD , Nunzio Bottini MD, PhD , Francesco Boin MD , Ahmed G.E. Ibrahim PhD, MPH , Eduardo Marbán MD, PhD","doi":"10.1016/j.jacbts.2024.08.008","DOIUrl":"10.1016/j.jacbts.2024.08.008","url":null,"abstract":"","PeriodicalId":14831,"journal":{"name":"JACC: Basic to Translational Science","volume":"9 12","pages":"Pages 1432-1434"},"PeriodicalIF":8.4,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11733755/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143005860","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Mechanisms of Skeletal Muscle Dysfunction in Cardiometabolic HFpEF and Its Reversal With Exercise Training","authors":"Bharathi Upadhya MD , Dalane W. Kitzman MD","doi":"10.1016/j.jacbts.2024.10.009","DOIUrl":"10.1016/j.jacbts.2024.10.009","url":null,"abstract":"","PeriodicalId":14831,"journal":{"name":"JACC: Basic to Translational Science","volume":"9 12","pages":"Pages 1426-1428"},"PeriodicalIF":8.4,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11733756/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143005082","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Partha Sardar MD , Juan F. Granada MD , Louis A. Cannon MD
{"title":"Revitalizing Innovation","authors":"Partha Sardar MD , Juan F. Granada MD , Louis A. Cannon MD","doi":"10.1016/j.jacbts.2024.08.006","DOIUrl":"10.1016/j.jacbts.2024.08.006","url":null,"abstract":"<div><div>Venture capital (VC) plays a critical role in driving advancements in medical device innovations through its investment in early-stage companies. However, a concerning trend has emerged over the past decade: a decline in interest from VC funds toward investing in medical devices. Particularly alarming is the more than 50% decrease in investment in early-stage medical device development over the span of 2 decades. In the last 2 years, there has been a significant drop in small to mid-cap VC funds allocated toward the cardiovascular (CV) device space. These obstacles are exacerbated by several factors, including high interest rates, inflation, global economic slowdown, and ongoing international conflicts. These declining investments stifle innovation and jeopardize the timely development of life-saving technologies, highlighting the urgent need for increased funding support. This manuscript delves into the pivotal role of VC in CV device innovation and examines the challenges and concerns stemming from the downturn in VC financing within the CV device sector.</div></div>","PeriodicalId":14831,"journal":{"name":"JACC: Basic to Translational Science","volume":"9 12","pages":"Pages 1435-1439"},"PeriodicalIF":8.4,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11733749/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143005415","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Bozhi Ye MD , Yanghao Chen MS , Xudong Chen MS , Diyun Xu BA , Yucheng Jiang BA , Wante Lin BA , Danhong Fang MS , Jiachen Xu BA , Jibo Han MS , Xue Han MS , Xiaohong Long MS , Wei Wang BA , Hao Zhou MD , Gaojun Wu MD , Guang Liang PhD
{"title":"Deubiquitinase USP25 Alleviates Obesity-Induced Cardiac Remodeling and Dysfunction by Downregulating TAK1 and Reducing TAK1-Mediated Inflammation","authors":"Bozhi Ye MD , Yanghao Chen MS , Xudong Chen MS , Diyun Xu BA , Yucheng Jiang BA , Wante Lin BA , Danhong Fang MS , Jiachen Xu BA , Jibo Han MS , Xue Han MS , Xiaohong Long MS , Wei Wang BA , Hao Zhou MD , Gaojun Wu MD , Guang Liang PhD","doi":"10.1016/j.jacbts.2024.06.001","DOIUrl":"10.1016/j.jacbts.2024.06.001","url":null,"abstract":"<div><div>Deubiquitinating enzymes play a vital role in cardiovascular diseases. This study found that cardiomyocyte ubiquitin-specific protease 25 (USP25) expression was downregulated both in myocardial tissue of obesity cardiomyopathy and palmitic acid–stimulated cardiomyocytes. USP25 deficiency exacerbated high-fat diet–induced ventricular remodeling in mice, whereas overexpression of USP25 in cardiomyocytes reversed this pathological phenotype. Mechanistically, USP25 directly binds to TAK1 and P62, and the 178-cysteine of USP25 removes the K63 ubiquitin chain from P62, which promotes the degradation of TAK1 through the autophagy-lysosome pathway, thereby ameliorating obesity-induced ventricular remodeling by reducing inflammation through the TAK1-MAPK pathway. This finding identifies USP25 as a potential therapeutic target for obesity cardiomyopathy.</div></div>","PeriodicalId":14831,"journal":{"name":"JACC: Basic to Translational Science","volume":"9 11","pages":"Pages 1287-1304"},"PeriodicalIF":8.4,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142697690","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ali Fatehi Hassanabad MD, MSc , Darrell D. Belke PhD , Paul M.K. Gordon PhD , Guoqi Teng MD, PhD , Jameson A. Dundas BSc , Anna N. Zarzycki BSc , Jeannine Turnbull BSc, MSc , Justin F. Deniset PhD , Paul W.M. Fedak MD, PhD
{"title":"Pericardial Fluid of Patients With Coronary Artery Disease Can Drive Fibrosis Via TGF-Beta Pathway","authors":"Ali Fatehi Hassanabad MD, MSc , Darrell D. Belke PhD , Paul M.K. Gordon PhD , Guoqi Teng MD, PhD , Jameson A. Dundas BSc , Anna N. Zarzycki BSc , Jeannine Turnbull BSc, MSc , Justin F. Deniset PhD , Paul W.M. Fedak MD, PhD","doi":"10.1016/j.jacbts.2024.06.007","DOIUrl":"10.1016/j.jacbts.2024.06.007","url":null,"abstract":"<div><div>Human pericardial fluid (PF) is a rich reservoir of biologically active markers. The acellular compartment of PF can drive cardiac fibroblast activity in vitro. This process is mediated through the transforming growth factor-β pathway. Of clinical importance, the PF of patients with coronary artery disease has an increased profibrotic capacity compared with the PF of patients without coronary artery disease.</div></div>","PeriodicalId":14831,"journal":{"name":"JACC: Basic to Translational Science","volume":"9 11","pages":"Pages 1329-1344"},"PeriodicalIF":8.4,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142697694","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"When Off-Target Is the Target","authors":"Jonathan A. Kirk PhD","doi":"10.1016/j.jacbts.2024.09.012","DOIUrl":"10.1016/j.jacbts.2024.09.012","url":null,"abstract":"","PeriodicalId":14831,"journal":{"name":"JACC: Basic to Translational Science","volume":"9 11","pages":"Pages 1326-1328"},"PeriodicalIF":8.4,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142697693","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Clarissa Becher MSc , Marius Wits MSc , Frances S. de Man Prof , Gonzalo Sanchez-Duffhues PhD , Marie-Jose Goumans Prof
{"title":"Targeting Soluble TGF-β Factors","authors":"Clarissa Becher MSc , Marius Wits MSc , Frances S. de Man Prof , Gonzalo Sanchez-Duffhues PhD , Marie-Jose Goumans Prof","doi":"10.1016/j.jacbts.2024.04.005","DOIUrl":"10.1016/j.jacbts.2024.04.005","url":null,"abstract":"<div><div>Pulmonary arterial hypertension (PAH) is a rare progressive disease characterized by pulmonary artery vascular remodeling, increased vascular resistance, and subsequent right ventricular hypertrophy and right heart failure. It is triggered by disrupted transforming growth factor (TGF)-β signaling, including loss-of-function mutations in the bone morphogenetic protein (BMP) receptor 2. Emerging treatments aim to inhibit elevated TGF-β levels or enhance diminished endothelial BMP signaling. This review aims to summarize the role of the TGF-β superfamily in the pathobiology of PAH and recent discoveries highlighting altered expression of TGF-β–related soluble factors in PAH patients that can serve as potential biomarkers and drug targets. The discussion focuses on how these altered factors can guide treatment decisions and monitor therapeutic responses, facilitating personalized patient care through the integration of diagnostics and therapy, that is, precision medicine. This approach tailors treatment strategies to individual patients based on their unique disease characteristics.</div></div>","PeriodicalId":14831,"journal":{"name":"JACC: Basic to Translational Science","volume":"9 11","pages":"Pages 1360-1374"},"PeriodicalIF":8.4,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142697696","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Yueshen Sun MB , Congting Guo BS , Zhan Chen BS , Junsen Lin BS , Luzi Yang MM , Yueyang Zhang BS , Chenyang Wu BS , Dongyu Zhao PhD , Blake Jardin MS , William T. Pu MD , Mingming Zhao PhD , Erdan Dong MD , Xiaomin Hu PhD , Shuyang Zhang MD , Yuxuan Guo PhD
{"title":"Non-Cell-Autonomous Cardiomyocyte Regulation Complicates Gene Supplementation Therapy for Lmna-Associated Cardiac Defects in Mice","authors":"Yueshen Sun MB , Congting Guo BS , Zhan Chen BS , Junsen Lin BS , Luzi Yang MM , Yueyang Zhang BS , Chenyang Wu BS , Dongyu Zhao PhD , Blake Jardin MS , William T. Pu MD , Mingming Zhao PhD , Erdan Dong MD , Xiaomin Hu PhD , Shuyang Zhang MD , Yuxuan Guo PhD","doi":"10.1016/j.jacbts.2024.06.004","DOIUrl":"10.1016/j.jacbts.2024.06.004","url":null,"abstract":"<div><div>The truncating mutations of <em>LMNA</em> are the major causes of cardiomyopathy. Here we studied 3 mouse models that carry germline, cardiomyocyte-specific, or genetic mosaic <em>Lmna</em> truncating mutations. Whereas the germline mutant manifested cardiac maturation defects, cardiomyocyte-specific mutation triggered pathological hypertrophy. In genetic mosaic analysis, no morphological defects were observed. Three adeno-associated virus (AAV) vectors were applied to addback lamin-A in a ubiquitous, cardiomyocyte-specific, or cardiomyocyte-excluded manner. Strikingly, only ubiquitous and cardiomyocyte-excluded AAV vectors mitigated the cardiac defects. Therefore, <em>Lmna</em> regulates cardiac morphology and function via a non-cell-autonomous mechanism. Noncardiomyocytes are key targets in AAV lamin-A therapy for <em>Lmna</em>-associated cardiac defects.</div></div>","PeriodicalId":14831,"journal":{"name":"JACC: Basic to Translational Science","volume":"9 11","pages":"Pages 1308-1325"},"PeriodicalIF":8.4,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142697692","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}